Recently, Shulan Medical Management Co., Ltd. (hereinafter referred to as "Shulan Medical") intends to IPO A shares, and CICC has been hired as a counseling institution for Shulan Medical's initial public offering of RMB ordinary shares (A shares) and listing.
It is reported that Shulan Medical is a comprehensive science and technology medical group integrating health and medical services, medical research, medical teaching and life science and technology. Shulan Medical's Hangzhou Headquarters Hospital, which began in 2015 with 1,000 approved beds and more than 1,500 employees, is the first large-scale social-run general hospital in China to pass the sixth edition of JCI.
On December 6, 2015, Shulan (Hangzhou) Hospital was officially opened, and the hospital as a whole was built in accordance with international JCI standards, with an initial investment of 500 million yuan, which is the largest, most functional and highest standard social force hospital in Zhejiang Province.
Shulan Medical legal person is Zheng Jie, who serves as the legal representative of 19 enterprises, Shulan Medical has experienced 5 financings, and the investment amount has not been disclosed.
It is worth mentioning that Zheng Shusen is currently the director of Shulan Medical, and Li Lanjuan once served as the chairman of Shulan Medical, stepping down from this position on December 1, 2020, in addition, Li Lanjuan and Zheng Shusen also appeared in the mentor lineup list of Shulan Medical's official website, so Shulan Medical was also interpreted by the market as an attempt to "academician medical treatment".